Neoplasms

Blood and Lymph Conditions

All Conditions

Leukemia

Hematologic Neoplasms

Hematologic Diseases

Anti-Infective Agents

Antineoplastic Agents

All Drugs and Chemicals

Cytarabine

Antimetabolites

Antiviral Agents

Immunosuppressive Agents

Immunologic Factors

CP-4055

Francis J Giles, MD

Patients with refractory or relapsed hematologic malignancies will receive CP-4055 intravenously(IV) on Day 1-5 every three weeks until complete response or disease worsening/progressing

This is a multicentre clinical study conducted in the USA and in Europe. It is an open label, dose escalation study designed to characterize the safety, tolerability, pharmacokinetics (PK), and efficacy of CP-4055 as a single agent when administered as a 2 hours intravenous (IV) or a continuous IV (CIV) infusion administered daily for 5 days in a 21-day cycle, either alone or with idarubicin IV, in patients with refractory/relapsed hematologic malignancies who have either failed potentially curative therapy or are considered unsuitable for standard therapy.

In a second phase of the study the efficacy of single agent CP-4055 in patients with AML may be assessed.

It is intended that patients receive a minimum of two cycles of therapy in the absence of unacceptable toxicity or significant disease progression.

A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies

Clavis Pharma

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies	NCT00405743	Hematologic Mal... AML	CP-4055 CP-4055	18 Years -	Clavis Pharma
A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies	NCT00405743	Hematologic Mal... AML	CP-4055 CP-4055	18 Years -	Clavis Pharma

Spots Global Cancer Trial Database for elacyt™

Every month we try and update this database with for elacyt™ cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for elacyt™

Every month we try and update this database with for elacyt™ cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for elacyt™ cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.